血清IL-17、IL-35及SIL-2R表达水平与甲状腺癌发生发展的关系

目的 通过检测IL-17、IL-35及SIL-2R在甲状腺癌患者血清中的表达水平，探讨其与甲状腺癌发生发展的关系。方法 采用酶联免疫吸附（ELISA）法分别检测67例甲状腺癌、30例甲状腺腺瘤、30例健康对照者血清中IL-17、IL-35及SIL-2R的水平，分析其与年龄、 性别、 病程进展、甲状腺癌病理类型、 病理分期的相关性。结果 甲状腺癌组血清IL-17及SIL-2R水平显著高于甲状腺腺瘤组和健康对照组（P<0.05），IL-35水平显著低于甲状腺腺瘤组和健康对照组（P<0.05）。随着甲状腺癌分化程度的降低，血清IL -17和SIL-2R水平呈上升趋势，IL-35水平呈下降趋势，且三组间两两比较差异均有统计学意义（P<0.05）。随着甲状腺癌临床分期的提高，IL-17和SIL-2R水平逐渐升高，IL-35水平逐渐降低，且各分期之间水平比较差异均有统计学意义（P<0.05）。但IL-17和SIL-2R水平在性别和年龄分层分析中差异均无统计学意义（P>0.05）。结论 IL-17、IL-35及SIL-2R水平可能与甲状腺癌的发生发展有关，测定其水平可作为临床病情观察和监测疗效的重要免疫学指标。

Relationship of Serum IL-17, IL-35, SIL-2R Levels with Occurrence and Development of Thyroid Cancer

Objective To detect the levels of IL-17, IL-35, SIL-2R in the serum, then to explore their relationship with the occurrence and development of thyroid cancer. Methods We used enzyme-linked immunosorbent(ELISA) to detect the plasma levels of IL-17, IL-35, SIL-2R in 67 cases of thyroid carcinoma, 30 cases of thyroid adenoma and 30 cases of healthy controls. And then we analyzed their correlation with age, gender, course of the disease, malignant degree of thyroid carcinoma and pathologic stage. Results The serum IL-17 and SIL-2R levels in the thyroid cancer group were significantly higher than those in the thyroid adenoma group and the control group(P<0.05). The level of serum IL-35 in the thyroid cancer group was significantly less than those in the thyroid adenoma group and the control group(P<0.05). With the decrease of differentiated degree of thyroid cancer, the serum levels of IL-17 and SIL-2R were increased, while the IL-35 level was decreased, and the comparison between each two groups had statistical difference(P<0.05). With the increase of thyroid cancer pathological staging, the serum levels of IL-17 and SIL-2R were on the rise, while the serum level of IL -35 showed a downward trend, and there were significant differences among different stages(P<0.05). But there was no significant difference between IL-17 and SIL-2R levels in the gender and age stratified analysis(P>0.05). Conclusion Plasma IL-17, IL-35 and SIL-2R levels may be associated with the occurrence and development of thyroid cancer, and measuring their levels could be used as the important immunological indexes for clinical observation and monitoring curative effect.